Drug Trial Radar · NCT06267846
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Mar 20, 2024
Primary completion
Jul 25, 2025
Study completion Sep 11, 2025
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Conditions
- Major Depressive Disorder
Interventions
NBI-1070770Drug
Suspension for oral administration
PlaceboDrug
Suspension for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5Time frame: Baseline, Day 5
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Little Rock, Arkansas
Neurocrine Clinical Site
Rogers, Arkansas
Neurocrine Clinical Site
Lemon Grove, California
Neurocrine Clinical Site
Long Beach, California
Neurocrine Clinical Site
Hollywood, Florida
Neurocrine Clinical Site
Maitland, Florida
Neurocrine Clinical Site
Decatur, Georgia
Neurocrine Clinical Site
Savannah, Georgia
Neurocrine Clinical Site
Gaithersburg, Maryland
Neurocrine Clinical Site
Dayton, Ohio
Neurocrine Clinical Site
North Canton, Ohio
Neurocrine Clinical Site
Houston, Texas
Neurocrine Clinical Site
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.